Eupraxia Reports Durable Symptom Relief in EoE Trial, Including First Odynophagia Data
EPRX sits 26% above its 52-week low of $5.04.
Summary
Eupraxia reported positive new symptom data from its RESOLVE trial in eosinophilic esophagitis, showing durable reductions in painful and difficult swallowing with no serious safety events.
Key Events · Product Development and Regulatory · EPRX
-
Odynophagia Data First Disclosed
Moderate-to-severe painful swallowing fell from 62% at baseline to 25% at weeks 24-52; severe cases dropped from 23% to 0%.
-
Dysphagia Improvement Confirmed
Moderate-to-severe difficulty swallowing fell from 77% at baseline to 25% at weeks 24 and 52; severe cases dropped from 31% to 0%.
-
Clean Safety Profile
No treatment-emergent or procedure-related serious adverse events in over 130 patients treated with EP-104GI or placebo across more than 2,000 injection sites.
-
Phase 2b Readout in Q4 2026
Interim data from the randomized, placebo-controlled Phase 2b portion of RESOLVE is expected in Q4 2026.
Analysis · EPRX · Life Sciences
New Phase 1b/2a RESOLVE data from Eupraxia show meaningful and durable reductions in both painful swallowing (odynophagia) and difficulty swallowing (dysphagia) through 52 weeks. Moderate-to-severe odynophagia fell from 62% to 25%, and severe cases dropped to zero at weeks 24 and 52. The safety profile remains clean with no serious adverse events across over 130 patients. This is the first time odynophagia data has been presented, adding a new efficacy dimension ahead of the Phase 2b placebo-controlled interim readout expected in Q4 2026.
At the time of this filing, EPRX was trading at $6.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $423.3M. The 52-week trading range was $5.04 to $9.32. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.